Industry news that matters to you.  Learn more

Archives for June 2014

QIAGEN Integrates Content From BIOBASE, Including Widely Adopted HGMD, With its Leading Offering for Biological Data Interpretation

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced the expansion of its industry-leading portfolio of bioinformatics solutions with additional content from BIOBASE, a provider of expertly curated biological databases, software and services. With access to HGMD, an especially in clinical markets widely used biomedical data resource as well as to other unique content, QIAGEN expand its world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis – further strengthening its market-leading position in the analysis and interpretation of sequencing data. QIAGEN’s growing bioinformatics and next-generation sequencing (NGS) franchises is positioned to benefit from the integration of BIOBASE, its assets and employees and will benefit the expansion of relationships with thousands of clinical labs and NGS users in life sciences.

Veracyte Presents Preliminary Data for Molecular Classifier to Improve Early, Non-Surgical Diagnosis of Idiopathic Pulmonary Fibrosis

Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of the first proof-of-concept data demonstrating the company’s ability to develop a molecular classifier to differentiate interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and its histological hallmark, usual interstitial pneumonia (UIP). The data were presented recently at the American Thoracic Society (ATS) 2014 International Conference in San Diego, Calif.

Multiple Studies Presented at ASCO Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX to Optimize Cancer Care

Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology ASCO Annual Meeting taking place May 30 – June 3 in Chicago, underscoring the practice-changing value of Oncotype DX in pre-invasive and invasive breast cancer and colon cancer.

Caris Life Sciences Presents ASCO Molecular Profiling Data Identifying Additional Therapy Options for Patients with Gastrointestinal (GI) Cancers

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data at the 50th Annual Meeting of ASCO in which molecular profiling identified numerous potential drug options in patients with various types of gastrointestinal (GI) cancer. Among nine total studies in GI cancer, two notable studies include a 14,000-plus, multi-ethnic international case-study of 17 different types of GI cancer, as well as a separate dataset, a subset of this large cohort, which analyzes nearly 7,000 colorectal cancer (CRC) patients to identify novel potential treatment options that might not otherwise have been considered.